Cryptome to collaborate with IMB
Tuesday, 07 December, 2004
Cryptome (ASX: CRP) has signed a memorandum of understanding with the Institute of Molecular Bioscience (IMB) to collaborate on the identification of cardiovascular therapeutics.
The company will combine the high throughput screening capabilities of Cryptomics platform technology, which is based on the identification of small protein fragments with previously undiscovered therapeutic activity, with the IMB's compound libraries, to identify compounds with therapeutic potential in the treatment of cardiovascular disease.
"Bringing together IMB's novel compound libraries and our screening capabilities will make a powerful combination in a most important clinical area," said Cryptome's acting CEO Prof Mathew Vadas.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
